PD-L1 antibody drugs are considered as the star of tumor immunotherapy, and it has been proved that tumor mutation burden (TMB) was closely related to the efficacy of PD-L1 antibody drugs in a variety of tumor [32, 33]. This evidence concerns the gene CD274 and neoplasm.